Heba Hrizat

Safety and efficacy of ertugliflozin on heart failure outcomes across cardiovascular diseases: a systematic review and meta-analysis

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular outcomes in patients with heart failure (HF) and type 2 diabetes (T2D). However, the efficacy of individual SGLT2is, particularly ertugliflozin, remains less defined. This systematic review and meta-analys...